Prevention of respiratory syncytial virus in children

Ugeskrift for Læger 2026 Open access

Read full text
Authors: Sidse Vang Braa Andersen, Lisbeth Samsø Schmidt, Ulla Birgitte Hartling, Anne‐Cathrine Finnemann Viuff, Mette Holm, Lone Graff Stensballe, Marie‐Louise von Linstow
DOI: 10.61409/v11250898
Cited by: 0
References: 20

Abstract

Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injections. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From October 2025, Denmark introduced a seasonal maternal vaccination, expected to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.

Fields of Study & Subjects

Respiratory viral infections research Pediatric health and respiratory diseases Neonatal Respiratory Health Research

Publication details

Journal / source
Ugeskrift for Læger
Volume
188
Issue
8
Pages
1–9
Publication date
16 February 2026
Language
DA